CW June 2006
Volume 15Issue Number 6 June 2006 ISSN 10593802 Adding Oxaliplatin to Fixed-Dose Gemcitabine: No Survival Benefit in Pancreatic CancerNeither fixed-dose rate infusion of gemcitabine, nor addition of oxaliplatin to standard gemcitabine treatment significantly improves survival in patients with pancreatic adenocarcinoma, according to Elizabeth Poplin, speaking at the American Society of Clinical Oncology 2006 Annual Meeting.
Go to Previous Page Go to Next Page Source & Additional Reading E. Poplin, speaking at the American Society of Clinical Oncology 2006 Annual Meeting. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW June 2006Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
